抗血栓薬/抗凝固薬：各種技術と世界市場

世界の抗血栓薬/抗凝固薬の市場規模は、2023年の316億米ドルから、予測期間中は7.9%のCAGRで推移し、2028年には462億米ドルの規模に成長すると予測されています。

トロンビン阻害剤の部門は、2023年の246億米ドルから、同期間中8.1%のCAGRで推移し、2028年には363億米ドルの規模に成長すると予測されています。また、抗血小板薬の部門は、2023年の40億米ドルから、7.8%のCAGRで推移し、2028年には58億米ドルの規模に成長すると予測されています。

当レポートでは、世界の抗血栓薬/抗凝固薬の市場を調査し、市場および技術の概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術および特許の動向、ESGの展開、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

• 心血管疾患の概要
• 冠動脈疾患
• アテローム性動脈硬化症
• 狭心症
• 急性心筋梗塞
• 医療管理
• ライフスタイルの変化
• 食事の修正
• 禁煙
• 医薬品
• 抗凝固薬と抗血小板薬
• 主な推進因子
• CVDの軽減を目的とした凝固因子
• 心血管疾患の世界的負担
• 心血管疾患の世界の経済的負担
• 2022年の主要医薬品の販売実績

第4章 世界の抗凝固薬市場

• 概要
• 製品
• 低分子量ヘパリン
• 経口抗凝固薬 (ビタミンK拮抗薬)
• 世界の抗凝固薬市場の予測

第5章 世界の抗血小板薬市場

• 概要
• 製品
• 経口抗血小板薬
• 世界の抗血小板薬市場の予測

第6章 世界のトロンビン阻害剤市場

• 概要
• 製品
• 直接的トロンビン阻害剤
• 血栓溶解剤
• 直接第Xa因子阻害剤
• 世界のトロンビン阻害剤市場の予測

第7章 世界の抗血栓薬/抗凝固薬市場：地域別

• 概要
• 北米
• 欧州
• アジア太平洋
• その他の地域

第8章 抗血栓薬/抗凝固薬市場の持続可能性：ESGの観点

• ESG：イントロダクション
• 抗血栓薬/抗凝固薬市場の持続可能性：ESGの観点から
• ESG上の主な問題
• ESGに対する消費者の意識
• 業界のESGパフォーマンス分析
• ケーススタディ
• BCCからの総論

第9章 臨床試験と特許の情勢

• 臨床試験分析
• 特許分析
• 特許：譲受人別

第10章 M&Aとベンチャー資金調達の見通し

• M&A分析

第11章 競合情勢

第12章 企業プロファイル

• BAYER AG
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL MYERS SQUIBB
• DAIICHI SANKYO CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• MERCK & CO. INC.
• PFIZER INC.
• SANOFI

第13章 付録

List of Tables

• Summary Table : Global Market for Antithrombotic/Anticoagulant Drugs, by Product Segment, Through 2028
• Table 1 : Standard Angina Pectoris Classification
• Table 2 : Top 20 Leading Causes of Death, 2019
• Table 3 : Estimated Deaths Due to Noncommunicable Diseases, by Sex and Disease, 2019
• Table 4 : Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2019
• Table 5 : Global Health Estimates, by Sex and WHO Region, 2019
• Table 6 : Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2030
• Table 7 : Estimated Deaths Due to Cardiovascular Disease, by Sex and WHO Region, 2030
• Table 8 : Economic Burden of NCDs in India, 2012-2030
• Table 9 : Praxbind (Idarucizumab) Drug Label
• Table 10 : Global Market for Thrombin Inhibitors Drugs, by Type, 2022
• Table 11 : Global Market for Anticoagulant Drugs, by Type, 2022
• Table 12 : Global Market for Antiplatelet Drugs, by Type, 2022
• Table 13 : Lovenox Drug Label
• Table 14 : Fragmin Drug Label
• Table 15 : Innohep Drug Label
• Table 16 : Global Market for Anticoagulant Drugs, by Region, Through 2028
• Table 17 : Global Market for Anticoagulant Drugs, by Type, Through 2028
• Table 18 : Global Market for Low Molecular Weight Heparin Anticoagulant Drugs, by Region, Through 2028
• Table 19 : Global Market for Oral Anticoagulant Drugs, by Region, Through 2028
• Table 20 : Plavix Drug Label
• Table 21 : Pletal Drug Label
• Table 22 : Effient Drug Label
• Table 23 : Global Market for Antiplatelets, by Type, Through 2028
• Table 24 : Global Market for Antiplatelets, by Region, Through 2028
• Table 25 : Global Market for Oral Antiplatelets, by Region, Through 2028
• Table 26 : Global IV Market for Antiplatelets, by Region, Through 2028
• Table 27 : Global Market for Thrombin Inhibitors, by Type, Through 2028
• Table 28 : Global Market for Thrombin Inhibitors, by Region, Through 2028
• Table 29 : Global Market for Direct Factor Xa Inhibitors, by Region, Through 2028
• Table 30 : Global Market for Direct Thrombin Inhibitors, by Region, Through 2028
• Table 31 : Global Market for Direct Thrombolytic Agents, by Region, Through 2028
• Table 32 : Global Market for Antithrombotic/Anticoagulant Drugs, by Region, Through 2028
• Table 33 : North American Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
• Table 34 : North American Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
• Table 35 : North American Market for Anticoagulant Drugs, by Type, Through 2028
• Table 36 : North American Market for Antiplatelets, by Type, Through 2028
• Table 37 : North American Market for Thrombin Inhibitors, by Type, Through 2028
• Table 38 : European Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
• Table 39 : European Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
• Table 40 : European Market for Anticoagulant Drugs, by Type, Through 2028
• Table 41 : European Market for Antiplatelets, by Type, Through 2028
• Table 42 : European Market for Thrombin Inhibitors, by Type, Through 2028
• Table 43 : Asia-Pacific Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
• Table 44 : Asia-Pacific Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
• Table 45 : Asia-Pacific Market for Anticoagulant Drugs, by Type, Through 2028
• Table 46 : Asia-Pacific Market for Antiplatelets, by Type, Through 2028
• Table 47 : Asia-Pacific Market for Thrombin Inhibitors, by Type, Through 2028
• Table 48 : Rest of the World Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
• Table 49 : Rest of the World Market for Anticoagulant Drugs, by Type, Through 2028
• Table 50 : Rest of the World Market for Antiplatelets, by Type, Through 2028
• Table 51 : Rest of the World Thrombin Inhibitors Drugs Market, by Type, Through 2028
• Table 52 : Key Focus Areas in ESG Metrics: Market for Antithrombotic/Anticoagulant Drugs
• Table 53 : Typical ESG Factors in Pharmaceuticals
• Table 54 : Net-Zero GHG Commitments by Major Antithrombotic/Anticoagulant Drug Manufacturing Companies
• Table 55 : ESG Rankings for Major Antithrombotic/Anticoagulant Drug Manufacturing Companies, 2023*
• Table 56 : CDP Scope Card for Major Antithrombotic/Anticoagulant Drug Manufacturing Companies, 2022
• Table 57 : Selected Thrombin Drugs in Clinical Trials, as of 2023
• Table 58 : Selected Granted Thrombosis Treatment Drugs in Clinical Trials, as of 2023
• Table 59 : Patents Issued on Anticoagulant Drugs, by Assignee Company, 2018-2022
• Table 60 : Patents Issued on Thrombin Inhibitor Drugs, by Assignee Company, 2018-2022
• Table 61 : Patents Issued on Antiplatelet Drugs, by Assignee Company, 2018-2022
• Table 62 : Global Market for Antithrombotic/Anticoagulant Drugs' Recent Mergers and Acquisitions
• Table 63 : Global Market for Antithrombotic/Anticoagulant Drugs Revenue Analysis, 2022
• Table 64 : Global Market for Antithrombotic/Anticoagulant Drugs Key Product Portfolio, 2022
• Table 65 : Global Thrombin Inhibitors Drugs Market Revenue Analysis, 2022
• Table 66 : Global Anticoagulants Drug Market Revenue Analysis, 2022
• Table 67 : Global Antiplatelet Drugs Market Revenue Analysis, 2022
• Table 68 : Bayer AG: Marketed Products
• Table 69 : Bayer AG: Key Financials, 2021 and 2022
• Table 70 : Bayer AG: Key Developments, 2022 and 2023
• Table 71 : Boehringer Ingelheim: Selected Key Developments, 2019-2021
• Table 72 : Bristol-Myers Squibb: Key Developments, 2020 and 2021
• Table 73 : Daiichi Sankyo: Product Information
• Table 74 : Daiichi Sankyo: Annual Revenue, 2020-2022
• Table 75 : Daiichi Sankyo: Key Developments, 2018-2023
• Table 76 : Roche: Financials, 2021 and 2022
• Table 77 : Roche: Revenues, by Business Segment, 2016-2021
• Table 78 : Roche: Product Portfolio
• Table 79 : Roche: Diagnostics Patient Monitoring Product Portfolio
• Table 80 : Roche: Recent Developments, 2019-2022
• Table 81 : Johnson & Johnson: Products Portfolio for Antithrombotic/Anticoagulant Drugs Treatment
• Table 82 : Johnson & Johnson: Financials, 2021
• Table 83 : Johnson & Johnson: Product Portfolio
• Table 84 : Johnson & Johnson: Recent Developments and Strategies, 2017-2022
• Table 85 : Merck & Co. Inc.: Products Portfolio for Antithrombotic/Anticoagulant Drug Treatment
• Table 86 : Merck & Co. Inc.: Financial Performance, 2018-2022
• Table 87 : Pfizer Inc.: Product Segments
• Table 88 : Pfizer Inc.: Key Financials, 2021
• Table 89 : Sanofi: Products Portfolio for Antithrombotic/Anticoagulant Drugs Treatment
• Table 90 : Sanofi: Business Segments
• Table 91 : Sanofi: Financial Performance,2021 and 2022
• Table 92 : Sanofi: Key Developments, 2019-2023
• Table 93 : Government Regulatory Agencies and Professional Organizations Associated with Cardiac Biomarkers

List of Figures

• Summary Figure : Global Market for Antithrombotic/Anticoagulant Drugs, by Product Segment, 2020-2028
• Figure 1 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2019
• Figure 2 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2019
• Figure 3 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2019
• Figure 4 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, 2019
• Figure 5 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2030
• Figure 6 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2030
• Figure 7 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2030
• Figure 8 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, 2030
• Figure 9 : Projected Total Costs of Cardiovascular Disease in the United States, 2015-2030
• Figure 10 : Global Market for Antithrombotic/Anticoagulant Drugs, by Region
• Figure 11 : Global Market Shares of Antithrombotic/Anticoagulant Drugs, by Region, 2022
• Figure 12 : How a Strong ESG Proposition Benefits Businesses
• Figure 13 : Global ESG-Adoption Level Across All the Industries, 2021 and 2022
• Figure 14 : The Ten Business Sustainability Trends Identified for 2022
• Figure 15 : Pfizer Inc.'s Most Material ESG Issues, 2020
• Figure 16 : Global Market Shares of Antithrombotic/Anticoagulant Drugs, by Company, 2022
• Figure 17 : Global Market Shares of Thrombin Inhibitors Drugs, by Company, 2022
• Figure 18 : Global Market Shares of Anticoagulant Drugs, by Company, 2022
• Figure 19 : Global Market Shares of Antiplatelet Drugs, by Company, 2022
• Figure 20 : Boehringer Ingelheim: Annual Revenue, 2021 and 2022
• Figure 21 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021 and 2022
• Figure 22 : Boehringer Ingelheim: Revenue Share, by Region, 2021 and 2022
• Figure 23 : Bristol-Myers Squibb: Revenue Share, by Region/Country, 2022
• Figure 24 : Daiichi Sankyo: Market Share, by Region/Country, 2022
• Figure 25 : Roche: Annual Revenue, 2021 and 2022
• Figure 26 : Roche: Market Share, by Business Segment, 2022
• Figure 27 : Roche: Revenue Share, by Business Segment, 2021
• Figure 28 : Roche: Revenue Share, by Region/Country, 2021
• Figure 29 : Johnson & Johnson: Financials, 2017-2021
• Figure 30 : Johnson & Johnson: Revenue Share, by Region/Country, 2021
• Figure 31 : Johnson & Johnson: Revenue Share, by Business Segment, 2021
• Figure 32 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2022
• Figure 33 : Merck & Co. Inc.: Revenue Share, by Region, 2022
• Figure 34 : Pfizer Inc.: Revenue Share, by Region, 2021
• Figure 35 : Pfizer Inc.: Revenue Share, by Business Segment, 2021
• Figure 36 : Sanofi: Net Sales Share, by Business Segment, 2022
• Figure 37 : Sanofi: Net Sales Share, by Region/Country, 2022

Highlights:

The global market for antithrombotic/anticoagulant drugs is estimated to grow from $31.6 billion in 2023 to reach $46.2 billion by 2028, at a compound annual growth rate (CAGR) of 7.9% from 2023 through 2028.

The global market for thrombin inhibitors is estimated to grow from $24.6 billion in 2023 to reach $36.3 billion by 2028, at a CAGR of 8.1% from 2023 through 2028.

The global market for antiplatelet drugs is estimated to grow from $4.0 billion in 2023 to reach $5.8 billion by 2028, at a CAGR of 7.8% from 2023 through 2028.

Report Scope:

This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market.

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028.

Report Includes:

• 59 data tables and 35 additional tables
• Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years
• Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region
• In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19
• A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity
• Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments
• Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers
• Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
• Profiles of the leading market players

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• What's New in This Report?
• Scope of Report
• Research Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Overview of Cardiovascular Disease
• Coronary Artery Disease
• Atherosclerosis
• Angina (Angina Pectoris)
• Acute Myocardial Infarction
• Medical Management
• Lifestyle Changes
• Diet Modification
• Smoking Cessation
• Pharmaceuticals
• Anticoagulants and Antiplatelet Drugs
• Major Drivers
• Coagulation Factors Targeted to Reduce CVD
• The Global Burden of Cardiovascular Disease
• 2030 Global Burden of Cardiovascular Disease
• The Global Economic Burden of Cardiovascular Disease
• Sales Performance of Major Drugs in 2022

Chapter 4 Global Market for Anticoagulant Drugs

• Overview
• Products
• Low Molecular Weight Heparin
• Oral Anticoagulants (Vitamin K Antagonists)
• Global Anticoagulant Drugs Market Forecast

Chapter 5 Global Market for Antiplatelet Drugs

• Overview
• Products
• Oral Antiplatelets
• Global Antiplatelet Drugs Market Forecast

Chapter 6 Global Market for Thrombin Inhibitors

• Overview
• Products
• Direct Thrombin Inhibitors
• Thrombolytic Agents
• Direct Factor Xa Inhibitors
• Global Thrombin Inhibitors Market Forecast

Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region

• Overview
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective

• Introduction to ESG
• Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
• Key ESG Issues
• Consumer Attitudes Towards ESG
• Industry ESG Performance Analysis
• Case Study
• Concluding Remarks from BCC

Chapter 9 Clinical Trials and Patent Landscape

• Clinical Trials Analysis
• Patent Analysis
• Patent by Assignee

Chapter 10 M&A and Venture Funding Outlook

• M&A Analysis

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

• BAYER AG
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL MYERS SQUIBB
• DAIICHI SANKYO CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• MERCK & CO. INC.
• PFIZER INC.
• SANOFI

Chapter 13 Appendix

• Government Regulatory Agencies and Professional Organizations